Health advocates and frontline health workers have taken the extraordinary step of formally asking the Office of the Ombudsman to remove Department of Health Secretary Jose "Brix" Pujalte Jr. from office, citing what they describe as an arbitrary and unexplained suspension of procurement for tuberculosis drugs and related commodities — a decision they argue puts thousands of patients directly at risk.

In a letter addressed to Ombudsman Jesus Crispin Remulla, the complainants characterize Pujalte's procurement freeze as tantamount to grave misconduct under Philippine administrative law. The filing is not a press release or a rally chant — it is a legal instrument that, if acted upon, could trigger a formal investigation and precautionary suspension of the secretary while the case is heard.

The core allegation is straightforward and damning: the DOH unilaterally halted the procurement of TB drugs and TB-related commodities without a transparent public health justification, without a published replacement supply plan, and without apparent legal basis sufficient to override the department's statutory mandate to ensure continuous access to medicines for communicable disease programs.

Tuberculosis is not a disease the Philippines can afford to treat casually. The country consistently ranks among the world's highest TB burden nations — a designation tracked by the World Health Organization's Global TB Report — with hundreds of thousands of active cases at any given time and a death toll measured in the tens of thousands annually. The National Tuberculosis Program, administered through the DOH, depends on uninterrupted drug supply to keep patients on the six-month treatment regimens that prevent both death and the development of drug-resistant strains.

Drug-resistant TB is the particular nightmare that makes supply disruptions so consequential. When patients are forced off treatment mid-course because drugs are unavailable — even temporarily — the bacteria they carry can develop resistance to first-line antibiotics. Multidrug-resistant TB requires longer, harsher, and vastly more expensive treatment. A procurement freeze that sounds like a bureaucratic inconvenience in a press statement is, at the patient level, a potential sentence to a far worse illness.

The DOH has not publicly released a detailed explanation of why the procurement was suspended, what the intended duration of the suspension is, or what contingency measures, if any, are in place to ensure patients currently enrolled in the national TB program do not experience treatment interruption. That silence is itself part of what the complainants appear to be targeting — the absence of transparency from a department that is legally obligated to account for how it manages public health resources.

Pujalte, a physician and former Samar representative, was appointed to lead the DOH under the Marcos administration. His tenure has not been without controversy, but this complaint represents the most direct legal challenge yet to his stewardship of the department. The Ombudsman's office has the power to place him under preventive suspension for up to six months while an investigation proceeds — a move that would carry significant political weight and effectively signal that the administration's health agenda is under formal scrutiny.

What the advocates are really demanding, beyond the legal proceeding, is accountability for a decision-making culture inside the DOH that treats procurement — the lifeline of any public health program — as an administrative lever to be pulled and pushed without public reckoning. Whether the Ombudsman acts swiftly or lets the complaint languish in its docket will itself be a signal about how seriously the current government takes the difference between managing a department and managing a disease.